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Infectious HPIV3 was produced by the intracellular coexpression of four plasmid-borne cDNAs. These separately encoded
a complete HPIV3 genome (negative-sense), the HPIV3 nucleocapsid protein N, the phosphoprotein P, and the polymerase
protein L. The cDNA-encoded HPIV3 genome differed from the JS wildtype (wt) strain of HPIV3 used in its construction
by seven point mutations: four of these are silent mutations in the HN or L gene coding regions that serve as markers of
a cDNA-derived virus, two were introduced to create an amino acid substitution that ablates an epitope recognized by the
HN-specific monoclonal neutralizing antibody 423/6, and the remaining point mutation results in an incidental amino acid
substitution in the HN protein at amino acid position 263. The four plasmids were transfected into HEp-2 cell monolayers
and their expression was driven by T7 RNA polymerase supplied by a vaccinia virus recombinant. The titer of virus present
in the harvested transfection supernatant was low (5 PFU/ml), and the recovered recombinant virus (rJS) retained each
of the seven mutations present in the cDNA from which it was derived. Despite the introduced and incidental mutations,
rJS retained the wt phenotypes as regards replication at elevated temperature in vitro and efficient replication in the upper
and lower respiratory tract of hamsters. rJS was also recovered from a cDNA encoding a complete antigenome (positive-
sense) with slightly greater efficiency than from the negative-sense construct. The ability to generate infectious HPIV3
from cDNA should greatly enhance our ability to develop new live-attenuated parainfluenza virus vaccines, including
chimeric PIV1 and PIV2 vaccines, and to understand the genetic basis of attenuation of PIV3 candidate vaccines. q 1997
Academic Press
INTRODUCTION (Karron et al., 1995a). The cp45 virus is protective against
HPIV3 challenge in experimental animals and is satisfac-
Human parainfluenza virus type 3 (HPIV3) is a signifi- torily attenuated, genetically stable, and immunogenic in
cant cause of serious lower respiratory tract infection in seronegative human infants and children (Hall et al.,
infants and children less than 1 year of age (Collins et 1992; Karron et al., 1995a).
al., 1996; Murphy et al., 1988). A vaccine has not been HPIV3 is a member of the paramyxovirus genus of the
approved for the prevention of HPIV3 disease nor is there paramyxovirus family. Its genome is a single strand of
effective antiviral therapy once disease occurs. There are negative-sense RNA that is 15,462 nucleotides (nt) in
two promising live-attenuated HPIV3 vaccine candidates length (Galinski et al., 1988; Stokes et al., 1992). It en-
undergoing clinical evaluation (Karron et al., 1995a,b). codes at least eight proteins: the nucleocapsid protein
First, a bovine PIV3 (BPIV3) that is antigenically related N, the phosphoprotein P, the proteins C and D, the matrix
to HPIV3 protects animals against HPIV3 infection and protein M, the fusion protein F, the hemagglutinin-neur-
has been found to be safe, attenuated, genetically stable, aminidase protein HN, and the large polymerase protein
and immunogenic in human infants and children (Karron L (Collins et al., 1996; Galinski, 1991; Spriggs and Collins,
et al., 1995b, 1996). Second, a cold-adapted HPIV3 mu- 1986). The M protein, HN protein, and F protein are asso-
tant has been generated by 45 serial passages of the ciated with the lipid envelope. The C protein is encoded
JS wildtype (wt) strain of HPIV3 in cell culture at low by an overlapping open reading frame (ORF) of the P
temperature (Belshe and Hissom, 1982). This live-attenu- protein mRNA (Spriggs and Collins, 1986).
ated, cold-passaged (cp) HPIV3 vaccine candidate, re-
Pertinent to the vaccines described above, a method
ferred to as cp45, exhibits the temperature-sensitive (ts),
for producing virus with a wt phenotype from cDNA is
cold-adaptation (ca), and attenuation (att) phenotypes
needed to determine which mutation(s) in the cp45 virus
specifies the ts, ca, and att phenotypes and which
gene(s) of the BPIV3 specifies the attenuation phenotype.1 To whom correspondence and reprint requests should be ad-
dressed at Laboratory of Infectious Disease, National Institute of Al- It also would be useful for developing new vaccines (Dis-
lergy and Infectious Disease, National Institutes of Health, 7 Center cussion) and for basic studies of molecular virology and
Drive, MSC 0720, Bethesda, MD 20892-0720. Fax: (301) 496-8312. pathogenesis. Manipulation of the genomic RNA of nega-E-mail: adurbin@nih.gov.
tive-sense RNA viruses has, until recently, been unsuc-2 Current address: Division of Infectious Diseases, St. Louis Univer-
sity Medical Center, 3635 Vista Avenue, St. Louis, MO 63110-0250. cessful because naked genomic RNA of these viruses is
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noninfectious. The genomic RNA of negative-stranded mg/ml gentamicin sulfate, and 2 mM glutamine. The JSwt
strain of HPIV3 and its attenuated ts derivative, JS cp45,viruses is tightly bound to the nucleocapsid protein N to
form the ribonucleoprotein complex that, in association were propagated in LLC-MK2 cells as described pre-
viously (Hall et al., 1992).with the phosphoprotein P, is the template for the RNA-
dependent RNA polymerase (large L protein) (Collins et
al., 1996). Functional nucleocapsids have been success- cDNAs
fully generated from the intracellular coexpression of
separately transfected plasmids bearing the T7 RNA A full cDNA clone, designated p218(131) (Fig. 1A), was
constructed to encode the complete 15,462-nt genomicpolymerase promoter and encoding either genomic or
antigenomic RNA, and the N, P, and L proteins. The intra- sequence of HPIV3 JS strain containing seven sequence
markers (Fig. 1B). A hepatitis delta virus ribozyme wascellular cDNA expression is driven by T7 RNA polymer-
ase which is produced by coinfecting a vaccinia recombi- placed abutting the 3* end of the genomic sequence so
that self-cleavage would yield the 3* end of HPIV3 (Per-nant virus. This approach was first used to determine
the transcription and replication requirements of cDNA- rotta and Been, 1991). A T7 transcription terminator was
placed following the delta ribozyme. The T7 promoterencoded minireplicons (for reviews see Conzelmann,
1996; Palese et al., 1996). The methodology has recently was placed adjacent to the 5* end of the genomic se-
quence such that the 5* terminal nucleotide of the HPIV3been extended to allow the recovery of infectious rabies
virus, vesicular stomatitis virus (VSV), measles virus, Sen- genome was the first nucleotide synthesized. In this con-
figuration, the cDNA encodes a complete negative-sensedai virus, and rinderpest virus from cDNA-encoded anti-
genomic RNA in the presence of the nucleocapsid N, copy of PIV3 genomic RNA containing the correct geno-
mic termini without any additional heterologous nucleo-phosphoprotein P, and large polymerase subunit L
(Baron and Barrett, 1997; Garcin et al., 1995; Kato et al., tides. A second cDNA clone designated p3/7(131) was
constructed to encode the complete antigenomic se-1996; Lawson et al., 1995; Radecke et al., 1995; Schnell
et al., 1994; Whelan et al., 1995). RSV has also been quence of HPIV3 (not shown). p3/7(131) differs from
p218(131) in that the positions of the T7 promoter andrecovered from cDNA-encoded antigenome, but this re-
quired the transfection of an additional plasmid encoding the ribozyme/T7 terminator relative to the HPIV3 cDNA
insert have been interchanged. Thus, the first nucleotidethe M2 ORF 1 transcription elongation factor (Collins et
al., 1995). synthesized in p3/7(131) is the 5* end of the antigenome,
namely the positive-sense complement of genome posi-We determined in our previous work with the HPIV3
minigenome system that the N, P, and L proteins ex- tion 1, and the 3* antigenome end defined by ribozyme
cleavage is the complement of genome position 15,462.pressed from cotransfected plasmids were the minimal
requirements for efficient transcription and RNA replica- A third clone designated p3/7(131)2G was constructed
identical to p3/7(131) except that two G residues weretion (Durbin et al., 1997). In this report, we describe the
recovery of infectious JSwt HPIV3 from cDNA. Initially, inserted between the 5* end of the antigenome and the
T7 promoter.infectious virus was recovered from cDNA encoding ge-
nomic-sense RNA. Since recovery of recombinant virus is Construction of p218(131). The HPIV3 cDNA was as-
sembled from 14 overlapping subclones (termed A*–L)generally believed to be more efficient from antigenomic
cDNA, we next constructed a cDNA encoding positive- constructed by reverse transcription (RT) and polymerase
chain reaction (PCR) of RNA isolated from virions purifiedsense antigenomic HPIV3 RNA. Recovery of infectious
virus from this latter construct was indeed more efficient, by sucrose gradient centrifugation (Stokes et al., 1992,
1993). The letters in parentheses designate the individualalthough the difference was not great. Importantly, we
demonstrate that the recovered virus manifests wt phe- plasmids and do not refer to specific viral genes. The
subclones spanned the following nucleotides of genomicnotypes in vitro and in vivo and therefore will serve as a
suitable substrate to define the attenuating mutations RNA (numbered with the 3* end being position 1): 1–
2058 (A*), 1874–3111 (A*), 3086–5140 (C), 4348–5276present in its derivative, the cp45 vaccine candidate, as
well as in the BPIV3 candidate vaccine virus. (C*), 5072–6695 (D*), 5904–8532 (E), 7806–9898 (F),
9632–10,740 (F*), 9760–10,955 (G), 10,862–11,925 (H),
11,835–12,868 (I), 12,426–13,677 (J), 13,630–14,496 (K),MATERIALS AND METHODS
and 14,467–15,462 (L). Each fragment was cloned into
Viruses and cells
pBluescript KS II (Stratagene, La Jolla, CA) using conven-
tional cloning techniques and was sequenced com-The modified vaccinia strain Ankara (MVA) recombi-
nant that expresses bacteriophage T7 RNA polymerase pletely.
p(L) was then subjected to site-directed mutagenesiswas generously provided by Drs. L. Wyatt and B. Moss
(Wyatt et al., 1995). HEp-2 monolayer cultures were main- to introduce the T7 promoter via a single-stranded DNA
intermediate according to the MUTA-GENE proceduretained at 377 in 5% CO2 with OptiMEM 1 (Life Technolo-
gies, Gaithersburg, MD) supplemented with 2% FBS, 50 (Bio-Rad, Hercules, CA). The T7 promoter was positioned
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FIG. 1. Diagram of JS cDNA [p218(131)] (not to scale) encoding a complete copy of HPIV3 negative-sense genomic RNA. (A) Positions are shown
for the hepatitis delta ribozyme, the T7 transcriptional terminator, and the T7 promoter. The HPIV3-specific region is defined by nucleotides 1–
15,462. The 5* and 3* ends are defined by the T7 promoter and the ribozyme, respectively, and are free of heterologous nucleotides. Each of the
seven introduced or incidental mutations is indicated by an asterisk. The cDNA encodes the complete negative-sense copy of HPIV3 genomic RNA.
T7 transcription is from right to left. (B) Sequence markers in cDNA encoded genomic RNA of the HN (1) and L (2) genes of HPIV3. Sequences are
positive sense, mutations are boxed. (1) A noncoding nt substitution at 7903 removed a HgaI site from JSwt. Nucleotide substitutions in JS cDNA
at 7913 and 7915 created a ScaI site and changed amino acid 370 from proline to threonine, ablating the antibody epitope recognized by mAb 170/
7 and 423/6. Also, the HN gene was found to contain an additional, incidental point mutation at nt 7593. This results in a threonine-to-isoleucine
change at amino acid position 263 in the HN protein. (2) The three incidental noncoding mutations in the L gene of JS cDNA that occurred during
plasmid construction or assembly are boxed.
so that transcription initiates at the precise 5* end of the T7 promoter adjacent to nucleotide 15,462 at the 5* end
of the genome. Subclones p(A*) to p(E) were assembledHPIV3 genome using the negative-sense mutagenic
primer: 5*-AATACGACTCACTATA*ACCAAACAAGAGAAC-3* into a second, overlapping subclone, p(A*A*CC*D*E),
which contained HPIV3 nucleotides 1–8533.(T7 sequences are italicized, HPIV3-specific sequences
are underlined, and the 5* end HPIV3 nucleotide, genome Both subclones p(E*FF*GHIJKL*) and p(A*A*CC*D*E)
were sequenced completely. In addition to the intro-position 15,462, is indicated by an asterisk). This modi-
fied p(L) was designated p(L*). p(E) was modified to yield duced point mutations described above, the cDNA dif-
fered from the authentic JS HPIV3 sequence (Stokes etp(E*) by the same method using the negative-sense mu-
tagenic oligonucleotide 5*-CCAAGTACTATGAGATGCT- al., 1992) by a single nucleotide substitution at position
1615, which was within the N gene and caused a substi-TCATT-3* to insert three nucleotide substitutions (under-
lined) into the HN gene at HPIV3 positions 7903, 7913, tution at amino acid 506 in the encoded protein. Three
other nucleotide substitutions were found at positionsand 7915 (Fig. 1B). These substitutions removed an HgaI
site, inserted a ScaI site, and modified amino acid 370 10,355, 11,333, and 15,248 in the L gene which did not
change the encoded protein (Fig. 1B). The last three non-of the encoded HN protein such that the epitope recog-
nized by monoclonal antibodies (mAb) 423/6 and 170/7 coding changes were retained as additional sequence
markers to identify recombinant virus (designated rJS)was ablated (van Wyke Coelingh et al., 1987). The p(E*)
to p(K) subclones were assembled in a step-wise fashion derived from cDNA, and the mutation in the N gene was
corrected as described later in this paper.into the p(L*) plasmid to give p(E*FF*GHIJKL*). This plas-
mid includes HPIV3 nucleotides 5904–15,462 with the p(A*A*CC*D*E) was then modified to insert the hepatitis
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delta virus ribozyme and T7 terminator adjacent to HPIV3 CGTAATACGACTCACTATAGGACCAAACAAGAG-3*
placed the T7 promoter (boldface type) adjacent to theposition 1. An HPIV3 minigenome in which the 3* end of the
HPIV3 genome (GGT f GGG) (underlined) was generated 5* end of the positive-sense HPIV3 antigenome (HPIV3
sequence underlined) with two G residues inserted be-through self-cleavage of a flanking hepatitis delta virus anti-
genomic ribozyme (shown in part in boldface type) was tween these two elements to improve transcription. A
unique MluI site (italicized) was placed upstream of thepreviously constructed (Dimock and Collins, 1993; Perrotta
and Been, 1991; Dimock and Collins, unpublished data). T7 promoter for cloning purposes. The negative-sense
primer 5*- 1224CGGCATCACGTGCTAC1209-3* spanned ntThe ribozyme in turn was followed by a T7 transcription
terminator. This minigenome cDNA was used as template 1209–1224 of the HPIV3 N gene and included a unique
PmlI site (italicized) present in the natural HPIV3 se-in a PCR which modified the sequence adjacent to the
ribozyme cleavage site to be a SmaI site (CCC f GGG) and quence. Both the PCR product and the parent template
p218(A*A*CC*D*E) were digested with MluI and PmlI andplaced an ApaI site (GGGCC f C) on the downstream side
of the T7 terminator. The PCR product was cloned into pKS the PCR product was then cloned into the MluI–PmlI
window. A second PCR was performed using the sameII which had been digested with BssHII and made blunt-
ended by filling in with dNTPs and T4 DNA polymerase, negative-sense primer and a positive-sense primer with-
out 2G residues inserted between the T7 promoter andyielding p218. The structure of the ribozyme was confirmed
by sequencing. p218 was designed such that any sequence the 5* end of the HPIV3 antigenome. These plasmids
were designated p(Left / 2G) and p(Left /).could be introduced into the opened SmaI site by blunt-end
ligation and its RNA transcript would be cleaved at the p(E*FF*GHIJKL*) was modified by PCR to place the delta
ribozyme and T7 terminator adjacent to the 3* end of thedelta ribozyme cut site (NNN f GGG). The p(A*A*CC*D*E)
subclone was digested with HgaI and SalI (8533), releasing HPIV3 antigenome. The positive-sense primer 5*-GGATTT-
GCGCGC14813AATTTAAATCATCTGG14828-3* introduced athe HPIV3 cDNA, which was filled in with dNTPs and T4
DNA polymerase to give blunt termini. The HgaI site is 10 BssHII site (italicized) just upstream of a unique naturally
occurring SwaI site (boldface, underlined) in the L gene ofnucleotides upstream of HPIV3 position 1 and, when di-
gested and filled in, leaves a blunt terminus beginning with HPIV3 (HPIV3 specific sequence is underlined). The nega-
tive-sense primer 5*-CCCAGGTCGGACCGCGAGGAG-HPIV3 position 1. The modified HgaI–SalI fragment was
gel-purified and cloned into the SmaI site of p218. The muta- GTGGAGATGCCATGCCAGCCC15462ACCAAAACAAGA-
GAAGAACTCTGTTTGG15435-3* placed a portion of the deltation in the N gene (T at nt 1615) was corrected to the
JSwt sequence (A at nt 1615) (see GenBank Accession No. ribozyme (the sequence complementary to the ribozyme is
shown in boldface type) which included a naturally oc-Z11575) using Kunkel mutagenesis (Kunkel et al., 1987). This
plasmid was designated p218(A*A*CC*D*E). curring unique RsrII site (italicized) adjacent to the 3* end
of the HPIV3 antigenome (shown here as the negative-The XhoI– NgoMI fragment of p(E*FF*GHIJKL*), which
contained the T7 promoter and the HPIV3 cDNA from sense complement, underlined). This PCR product was di-
gested with BssHII and RsrII and cloned into the BssHII–nucleotide 7438 to 15,462, was cloned into the XhoI–
NgoMI window of p218(A*A*CC*D*E). This joined the RsrII window of plasmid p3/7. Plasmid p3/7 is identical to
p218 except that the delta ribozyme and T7 terminator aretwo fragments of HPIV3 cDNA at HPIV3 nucleotide 7438,
yielding a plasmid containing a full-length HPIV3 cDNA in the reverse orientation. The p3/7 plasmid containing the
above-mentioned insertion was designated pPIV3-3/7 andencoding a negative-sense genomic RNA with the above-
mentioned three desired mutations in the HN gene and contained the complete delta ribozyme and T7 terminator
adjacent to the 3* terminal 651 nucleotides of the HPIV3three incidental mutations in the L gene. The final con-
struct, designated p218(131), was then sequenced in its antigenome. The SwaI and NgoMI fragment of plasmid
pPIV3-3/7 was then isolated and cloned into the SwaI–entirety by automated sequencing at the NCI Frederick
Cancer Research and Development Center (Frederick, NgoMI window of p(E*FF*GHIJKL*). The resulting plasmid,
designated p(Right /), placed the complete delta ribozymeMD) using the Taq Dye Deoxy Terminator Cycle Se-
quencing kit (ABI, Foster City, CA). This identified an and T7 terminator adjacent to the 3* end of the HPIV3
antigenome. The XhoI–NgoMI fragment of p(Right /) wasadditional change, namely from C to T in the HN gene
at position 7593, which changed HN amino acid 263 cloned into the XhoI–NgoMI window of p(Left/) and p(Left
/ 2G), resulting in plasmids p3/7(131) and p3/7(131)2G,from threonine to isoleucine as indicated in Fig. 1B. This
served as an additional, seventh sequence marker. respectively. Each of these encodes the complete positive-
sense analog of HPIV3 antigenomic RNA, with the latterConstruction of p3/7(131)2G and p3/7(131). The two
plasmids p218(A*A*CC*D*E) and p(E*FF*GHIJKL*) were cDNA containing two G residues adjacent to the T7 pro-
moter for improved transcriptional efficiency.modified and joined to encode the complete positive-
sense antigenome of HPIV3. First, the T7 terminator and
Transfectionthe delta ribozyme abutting the 3* end of HPIV3 in
p218(A*A*CC*D*E) were replaced by a T7 promoter using HEp-2 cells were grown to 90% confluence in six-well
plates. Each well of a six-well plate (1.5 1 106 cells) wasPCR. The positive-sense primer 5*-GGCCCGTCGACG-
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transfected with the three previously described support layers on 24-well plates in serial 10-fold dilutions, al-
lowed to adsorb for 1 hr at room temperature, overlaidplasmids (Durbin et al., 1997) 0.4 mg pTM(P), 0.4 mg
pTM(N), and 0.05 mg pTM(L), together with 5 mg of full- with 1 ml of L-15 supplemented with 2 mM glutamine
and 0.8% methylcellulose, and then incubated for 5 dayslength genomic or antigenomic HPIV3 cDNA. The plas-
mids were added to 0.2 ml of OptiMEM 1 (Life Technolo- at the indicated temperature. The methylcellulose overlay
was removed and the monolayer fixed with 80% methanolgies) containing 12 ml of LipofectACE (Life Technologies).
After an incubation period of approximately 15 min at at 47 for 1 hr. The viral plaques present in the monolayer
were immunostained with a mixture of two HPIV3-spe-room temperature, 0.8 ml of OptiMEM 1 containing 2%
fetal bovine serum and 1.5 1 107 PFU of MVA-T7 was cific anti-HN murine mAbs 101/1 and 66/4 as ascites fluid
used at a dilution of 1:500, using an immunoperoxidaseadded to each well. The cultures were incubated at 327
for 12 hr, after which the medium was replaced with method specific for murine antibodies as previously de-
scribed (Murphy et al., 1990).fresh OptiMEM 1 containing 2% fetal bovine serum. The
cultures were incubated at 327 for an additional 3 days
and then the cell supernatant was harvested and pas- Hamster studies
saged (referred to as passage 1) onto fresh HEp-2 mono-
Groups of nine 16-week-old golden Syrian hamsterslayers. These passage 1 cultures were incubated at 327
were inoculated intranasally with 0.1 ml OptiMEM 1 con-for 5 days, and virus present in the cell supernatant was
taining 105.5 PFU of rJS recovered from negative-senseharvested, passaged once in LLC-MK2 cultures, and
cDNA, rJS recovered from positive-sense cDNA, JS cp45,characterized by hemagglutination-inhibition (HAI) as de-
or JSwt. On Day 4 postinfection, the hamsters were sacri-scribed previously (van Wyke Coelingh et al., 1985) to
ficed and the lungs and nasal turbinates were harvested.determine if it possessed the monoclonal antibody-resis-
The lungs were homogenized in a 20% w/v L-15 suspen-tant mutation (MARM) that marked virus recovered from
sion containing 2.5 mg/ml amphotericin B (Quality Biolog-cDNA.
icals), 200 mg/ml pipericillin (Lederle), and 50 mg/ml gen-
tamicin (Quality Biologicals). Similarly, the nasal turbi-Sequencing of recovered recombinant (designated
nates were homogenized in a 10% w/v L-15 suspension.rJS) virus
After homogenization, the samples were aliquoted and
The presence of nucleotide sequence markers in the rapidly frozen in a dry–ice–ethanol bath. Virus present
HN and L genes of rJS (Fig. 1B) was determined by RT- in the samples was titered at a later date in 96-well plates
PCR of RNA isolated from recovered virions. Virus parti- of LLC-MK2 cells at 327. CPE was scored at 5 and 7 days
cles were precipitated from 1 ml of rJS (1 1 105 PFU/ml, after inoculation. The mean log10 TCID50/g was calculated
passage level 2) by the addition of 200 ml 25% polyethyl- for each group of nine hamsters.
ene glycol, incubation on ice for 1 hr, and centrifugation
at 12,000 g for 15 min. The RNA was purified with TRIzol RESULTS AND DISCUSSION
reagent (Life Technologies) following the manufacturer’s
Construction and rescue of recombinant JS strainrecommended procedure. RT-PCR was performed with
of HPIV3 from cDNA encoding negative-sensethe Superscript kit (Life Technologies) following the man-
genomic RNA (referred to as rJS-NS)ufacturer’s recommended protocol. Control reactions
were identical except that reverse transcriptase was
A cDNA clone [p218(131)] encoding the complete ge-
omitted from the reaction to confirm that the PCR prod-
nome of the HPIV3 JS strain was constructed as de-
ucts were derived solely from viral RNA and not from
scribed under Materials and Methods. p218(131) was
possible contaminating cDNA plasmids. Four primer
designed such that the T7 promoter was placed adjacent
pairs were used to generate PCR products from nt 7334 –
to the 5* trailer of the HPIV3 genome and the hepatitis
8715, 9364–10,854, 10,939–15,392, and 13,623–15,392.
delta virus ribozyme directly abutted the 3* leader so that
The resultant PCR products were then sequenced using
cleavage of the ribozyme would generate the 3* end of
cycle dideoxynucleotide sequence analysis (New En-
the HPIV3 genome free of additional heterologous nucle-
gland Biolabs, Beverly, MA).
otides. Three mutations were introduced into the HN
gene to distinguish cDNA-recovered virus from wt virusEfficiency of plaque formation of rJS at permissive
(Fig. 1B). These mutations, at nucleotides 7903, 7913,and restrictive temperatures
and 7915, removed an HgaI site from the genome and
introduced a proximal ScaI site. The mutations at nt 7913The level of temperature sensitivity of replication in
vitro of control viruses and rJS derived from both and 7915 also obliterated an antibody epitope recognized
by the HPIV3-specific mAbs 423/6 and 170/7 and there-p218(131) and p3/7(131)2G was determined at 32, 37, 39,
and 407 in LLC-MK2 monolayer cultures as previously fore served as a marker to readily distinguish JSwt virus
from rJS-NS. A fourth mutation in the HN gene at nt posi-described with the following modifications (Hall et al.,
1992). Viruses were inoculated onto LLC-MK2 mono- tion 7593 (C r T) was found during sequence analysis
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TABLE 1
rJS-NS Contains the MARM Mutation Introduced in the p218(131) Full-Length Negative-Sense cDNA
Hemagglutination-inhibiting antibody titer (reciprocal mean log2)a of indicated mAb
Virus 77/5b 101/1b 454/11b 170/1c 423/6c
JSwt d 8.7 { 0.9 11 { 1.4 11.0 { 1.15 11.7 { 0.7 12 { 0.58
rJS-NSe 9.7 { 0.9 12 { 0.6 11.7 { 1.33 £2 { 0 £2 { 0
a Mean log { standard error for three separate experiments.
b mAb 77/5 recognizes antibody epitope IIB, and mAbs 101/1 and 454/11 recognize antibody epitope IIIA of the HN glycoprotein, none of which
were altered in p218(131).
c Mabs 170/7 and 423/6, both of which recognize antibody epitope I of JSwt, fail to recognize rJS due to the MARM mutation at this site.
d Biologically derived wildtype HPIV3 JS.
e Recombinant JS virus derived from negative-sense genomic cDNA.
of the completed p218(131) full-length clone (Materials rJS-NS contained each of the seven markers. Sequencing
data showing three of the markers are illustrated in Fig.and Methods). This mutation resulted in a coding change
(threonine to isoleucine) at amino acid 263 of the HN 2. The sequence differences (Fig. 2) between rJS-NS and
JSwt in the HN gene, including nt 7903, 7913, and 7915,gene. Three noncoding mutations were present in the L
gene at nt positions 10,355, 11,333, and 15,248. The HN are readily apparent. Similar sequence analyses were
carried out for the other four markers at nt positions 7593,mutation at position 7593 and the three L gene mutations
occurred inadvertently during the generation of p(E*FF*- 10,355, 11,333, and 15,248, which confirmed that rJS-NS
possessed each mutation (data not shown).GHIJKL*). These four mutations were left uncorrected to
serve as additional markers for virus recovered from
cDNA. Thus, the sequence of p218(131) differed from Construction and recovery of recombinant virus from
that of wt HPIV3 strain JS at a total of seven nucleotide cDNA encoding positive-sense antigenomic RNA
positions.
p218(131) and the three support plasmids pTM(N), The results described above demonstrated the suc-
cessful recovery of infectious rJS from cDNA encodingpTM(P), and pTM(L) were transfected into HEp-2 cells
with MVA expressing T7 RNA polymerase. A control negative-sense genomic RNA. This differs from most
published reports for recovery of other nonsegmentedgroup consisting of pTM(N), pTM(P), pTM(L), and MVA
was cotransfected into HEp-2 cells without p218(131). negative-strand RNA viruses, in which the cDNA used
for virus recovery had been designed to encode positive-On Day 4, the transfected cells were harvested, and the
supernatant was passaged onto fresh HEp-2 cell mono- sense antigenomic RNA (Baron and Barrett, 1997; Collins
et al., 1995; Conzelmann, 1996; Garcin et al., 1995; Law-layers, incubated for 5 days, and passaged again for 5
days in LLC-MK2 cultures (passage 2). Virus present in son et al., 1995; Radecke et al., 1995; Whelan et al., 1995).
The recovery of infectious virus from a cDNA encodingthe passage 2 harvest was further characterized by HAI.
Cultures from the transfection group which received the genomic RNA had previously been reported only in the
case of Sendai virus, and the efficiency of recovery wasthree support plasmids without the full-length genomic
clone p218(131) did not yield HPIV3. The rJS-NS recov- much lower than for cDNA encoding antigenomic RNA
(Kato et al., 1996). In other studies, the recovery of virusered virus was confirmed to be HPIV3 since it reacted
in the HAI assay with mAbs 77/5, 101/1, and 454/11, was achieved with antigenomic cDNA but not with geno-
mic cDNA (Lawson et al., 1995; Whelan et al., 1995).which are specific for HPIV3 (Table 1). It was presump-
tively identified as being cDNA-derived because it failed One possible explanation which was suggested was that
cDNA-encoded genomic RNA might anneal to mRNA pro-to react with mAbs 170/7 and 423/6, consistent with the
MARM mutation which had been introduced into the duced by the support plasmids, resulting in inactive hy-
brids (Conzelmann, 1996; Lawson et al., 1995). It also wascDNA (Table 1).
To confirm that rJS-NS was indeed recovered from noted that T7 RNA polymerase appeared to terminate
preferentially at the gene junctions of genomic RNA, per-cDNA, it was analyzed in parallel with wildtype JS strain
HPIV3 by RT-PCR using four primer pairs flanking the haps because the oligo(U) tract of the gene-end signal
resembles the natural signal for transcription terminationseven inserted marker mutations. Each PCR product ob-
tained was dependent upon the inclusion of RT, indicat- by T7 RNA polymerase (Whelan et al., 1995).
Therefore, we modified the cDNA in order to createing that each was derived from RNA and not from con-
taminating cDNA (data not shown). Cycle sequencing of p3/7(131), which encodes the positive-sense anti-
genome, and p3/7(131)2G, which is identical to p3/7(131)the four PCR products confirmed that the sequence of
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FIG. 2. Sequence confirmation of sequence markers in recombinant virus rJS-NS. A 1379-bp fragment (nucleotides 7334–8713) spanning the
mutations at 7903, 7913, and 7915 was generated by RT-PCR of RNA from infected cells and then analyzed by cycle sequencing. The mutations
differentiating rJS from JSwt are indicated by arrows. The complete sequence from nt 7897 to 7922 is shown in the margin next to each gel, with
the three nucleotide differences indicated by boxes.
with the addition of two G residues between the T7 pro- frequently recovered from cultures transfected with p3/
7(131)2G than from cultures transfected with p218(131).moter and the first nucleotide of the antigenome. The
addition of two G residues between the T7 promoter Since each transfection harvest, including those with
p218(131), yielded rJS in experiment 2, it was not possibleand the first HPIV3 nucleotide is based on our previous
studies with HPIV3 minireplicons which showed that the to use this method of analysis to compare the relative
efficiency of generating recombinant virus. We thereforepresence of the two added G residues (as opposed to
zero, one, or three added G residues) was associated estimated the relative quantity of virus present in the
transfection harvest by quantitating the amount of viruswith the maximum levels of minireplicon replication (Dur-
bin et al., 1997). Thus, these two modifications would be following one passage of the transfection harvest (Table
2). Since each plasmid was designed to yield an identicalexpected to increase the efficiency of recovery of rJS,
and the two cDNAs provided the opportunity to examine virus (rJS), differences in titers of the passaged virus were
considered a reflection of differences in the titer of virusseparately the effects of each modification.
The two antigenome cDNAs were transfected sepa- present in transfection harvest. In experiments 1 and 2,
the construct with two 5* terminal G residues was therately into cells together with the N, P, and L support
plasmids, and they were infected simultaneously with most efficient in generating rJS. This indicated that the
two added residues indeed increased the efficiency ofthe MVA-T7 recombinant virus using the procedure de-
scribed above for p218(131). Infectious virus from each recovery, but the mechanism for this small increment in
efficiency was not defined. These findings indicate aantigenomic cDNA was recovered and was presump-
tively identified as being cDNA-derived by its inability to small, but measurable, advantage of using p3/7(131)2G
as substrate for future experiments designed to introducereact with mAbs 423/6 and 170/7 (not shown).
The efficiency of recovery of recombinant virus from mutations into the HPIV3 cDNA. The small advantage in
recovery of recombinant virus from p3/7(131)2G might bethe three full-length plasmids encoding the genomic or
antigenomic HPIV3 RNAs was next studied: (i) to deter- especially needed to recover viruses that have attenuat-
ing mutations that restrict replication in vitro. Althoughmine whether genomic or antigenomic cDNA is more
efficient at generating recombinant virus and (ii) to deter- VSV has been recovered from antigenomic cDNA which
included three G residues at the 5* terminal end, themine the effect of two extra 5* terminal G residues on
the yield of recombinant viruses (Table 2). Unfortunately, efficiency of recovery of virus from this construct was not
compared with recovery from the same construct lackingit was not possible to directly titer the transfection har-
vest by plaque titration because residual MVA-T7 inter- the extra residues (Whelan et al., 1995). In contrast to
the experience with Sendai virus and measles virus, itfered with plaque formation of rJS on LLC-MK2 mono-
layer cultures. Therefore, we first compared the efficiency is clear that extraviral G residues at the 5* terminal end
of the antigenome are not deleterious to recovery of re-of recovery of rJS from multiple independent transfections
and, as seen in experiment 1, found that rJS was more combinant virus and, in fact, appear to be advantageous
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TABLE 2
Comparison of the Efficiency of Recovery of Recombinant Virus from cDNAs Encoding Genomic or Antigenomic RNA,
the Latter with or without 2G Residues added to the T7 Promoter
Mean titer (log10 PFU/ml)
Experiment Transfected cDNA Sense of encoded RNA Rescue efficiencya of recovered virusb
1 p3/7(131)2Gc Antigenomic 12/12 (100%) 5.0 { 0.27
p218(131) Genomic 4/12 (33%) 4.1 { 0.27
2 p3/7(131)2Gc Antigenomic 6/6 (100%) 6.6 { 0.18
p3/7 (131) Antigenomic 12/12 (100%) 5.3 { 0.12
p218(131) Genomic 5/5 (100%) 4.9 { 0.19
a Number of transfection cultures yielding rJS/number tested.
b The mean titer { standard error was determined following one passage of transfection harvest for 5 days in LLC-MK2 cells.
c Contains two G residues between the T7 promoter and the 5* end of the antigenome.
(Garcin et al., 1995; Kato et al., 1996; Radecke et al., exhibited a 100-fold reduction in titer at 377 and failed to
produce plaques at 39 or 407. The sequence of JS cp451995). The genomic and antigenomic plasmids without
two 5* terminal guanine residues appeared equally effi- has been fully determined (Stokes et al., 1993) and muta-
tions have been identified in the leader, P, M, F, HN, andcient in generating recombinant virus. This is in contrast
to previous reports which have found genomic cDNA to L genes. However, it is unknown which mutation(s) is
responsible for the ca, att, or ts phenotypes. Becausebe less efficient than antigenomic cDNA in generating
recombinant virus (Kato et al., 1996; Whelan et al., 1995). rJS-NS and rJS-PS demonstrate the ts/ phenotype like
their JSwt parent, we can now introduce each of the
Characterization of the level of temperature known cp45 mutations, either alone or in combination,
sensitivity of rJS-NS and rJS-PS into the full-length cDNA and evaluate the level of replica-
tion of the recombinant virus at elevated temperature.Recombinant viruses derived from either positive- or
The mutation(s) responsible for the ts phenotype cannegative-sense cDNA were characterized by plaque
be identified in this manner and, if possible, altered byassay at 32, 37, 39, and 407 to determine if they were
mutagenesis to contain two or more nucleotide substitu-phenotypically similar to JSwt virus. rJS-PS and rJS-NS
tions per codon to make a recombinant cp45 virus thatwere comparable to the JSwt virus in their level of replica-
is more genetically stable.tion at elevated temperatures of 39 and 407 (Table 3).
This indicated that neither the sequence markers nor the
Replication of rJS viruses in hamstersincidental mutations acquired during cDNA construction,
in particular the HN coding change at position 263, af- Each recombinant virus was then administered to
fected virus growth or rendered it temperature sensitive. hamsters to determine if it retained the wt phenotype of
These changes also were phenotypically silent when the efficient replication in the upper and lower respiratory
virus replicated in the respiratory tract of hamsters (see tracts. Table 4 illustrates that rJS-NS and rJS-PS replicate
below). This is in contrast to the ts mutant JS cp45, which to the same level as JSwt in the upper and lower respira-
tory tract of hamsters. This is in contrast to the JS cp45
virus which is attenuated at each site. Thus, it is clearTABLE 3
that rJS retains the replicative capacity of its biologically
The rJS Resembles Its Biologically Derived Parent JS Wildtype Virus derived JSwt parent in hamsters, and mutations present
in the Level of Replication at Restrictive Temperature (39–407)
in the JS cp45 candidate vaccine that restrict replication
in hamsters can now be readily identified.Virus titer (log10 PFU/ml)
The replication of the BPIV3 candidate vaccine has not
Virus 327 377 397 407 been tested in hamsters, but it possesses host-range
mutations that restrict its replication in rhesus monkeys
rJS-PSa 6.1 6.1 6.1 6.6
and humans (Karron et al., 1995a; van Wyke Coelingh etrJS-NSb 6.9 7.1 7.1 7.0
al., 1988). The replicative capacity of rJS in rhesus mon-JScp45c 6.3 4.3 0.7 0.7
JSwt 6.5 6.8 6.6 6.7 keys is currently being compared with that of JSwt. If rJS
virus replicates like JSwt to high titer in the upper and
a Recombinant virus derived from the antigenomic-sense clone lower respiratory tract of rhesus monkeys, then the
p3/7(131)2G.
gene(s) or cis-acting regulatory sequences of the BPIV3b Recombinant virus derived from the genomic-sense clone
that specify the host-range restriction can be identifiedp218(131).
c JScp45 is a temperature-sensitive mutant derived from JSwt. by their substitution for the corresponding sequences in
AID VY 8697 / 6a3f$$$401 07-31-97 10:17:21 vira AP: VY
331RECOVERY OF INFECTIOUS HPIV3 FROM cDNA
TABLE 4 studying the molecular biology and pathogenesis of this
important human pathogen.The rJS Resembles Its Biologically Derived Parent JSwt Virus in
the Level of Replication in the Upper and Lower Respiratory Tract of Note added in proof. We acknowledge the successful recovery of
Hamsters another strain of parainfluenza virus type 3 from cDNA by M. Hoffman
and A. Banerjee (1997 J. Virol. 71, 4272–4277), which was reported
Mean virus titer (log10 TCID50/g)a after the submission of this article.
Virus Nasal turbinates Lungs
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